Pricing Log in Create free account

AC Immune (ACIU) vs Immuneering Corporation (IMRX)

AC Immune and Immuneering Corporation are both Biotechnology companies. AC Immune and Immuneering Corporation are of similar size ($238.3M and $227.0M). AC Immune grew revenue faster over the last twelve months: −78.6% against −84.8%. Immuneering Corporation has the higher net margin (0.00% vs −962.2%) and the lower return on invested capital (−198.4% vs 0.00%). Across the 15 metrics below, Immuneering Corporation leads on 9 and AC Immune on 6.

Valuation

Metric ACIU IMRX Biotechnology median
P/E n/m n/m 10.60
P/S 21.29 751.21 9.40
P/B 4.52 1.41 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 9.06 292.52 9.02
Earnings yield (32.74%) (28.10%) (32.88%)
Free cash flow yield (55.75%) (25.95%) (23.13%)

Profitability

Metric ACIU IMRX Biotechnology median
Gross margin 100.00% 0.00% 68.51%
Operating margin (986.55%) 0.00% 0.00%
Net margin (962.17%) 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (122.01%) (33.53%) (51.96%)
Return on assets (33.75%) (31.40%) (46.06%)
Return on invested capital 0.00% (198.38%) 0.00%

Growth

Metric ACIU IMRX Biotechnology median
Revenue growth (TTM) (78.60%) (84.76%) 6.76%
EPS growth (last fiscal year) (44.83%) 37.75% 29.88%
Revenue growth, 5-year CAGR (47.84%) — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACIU IMRX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.85 13.97 4.97
Net debt to EBITDA 1.37 2.94 1.01

Dividend

Metric ACIU IMRX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ACIU IMRX Biotechnology median
Market cap 226.96m 238.33m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack